Drug Trial Radar · NCT03056209
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jun 26, 2017
Primary completion
Apr 16, 2018
Study completion Apr 16, 2018
Sponsor
- Lead sponsor
- Yungjin Pharm. Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this First In Human study is to investigate the safety and tolerability of KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of KL1333 after a single oral dose.
Conditions
- MELAS Syndrome
- Mitochondrial Respiratory Chain Deficiencies
Interventions
KL1333 25 mgDrug
oral administration, single dose, 25 mg 1 tab
KL1333 50 mgDrug
oral administration, single dose, 25 mg 2 tabs
KL1333 100 mgDrug
oral administration, single dose, 100 mg 1 tab
KL1333 200 mgDrug
oral administration, single dose, 100 mg 2 tabs
KL1333 400 mgDrug
oral administration, single dose, 100 mg 4 tabs
KL1333 600 mgDrug
oral administration, single dose, 100 mg 6 tabs
KL1333 800 mgDrug
oral administration, single dose, 100 mg 8 tabs
PlaceboDrug
oral administration, placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of reported adverse eventsTime frame: from day 1 to day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.